Youjia Bio Recognized as National High-Tech Enterprise and Files IPO Prospectus
YOUJIA BIO
Nucleic Acid Drug Developer
Recently, the Office of the National Leading Group for the Identification and Management of High-tech Enterprises released the "Notice on the Record-filing Public Announcement of High-tech Enterprises Identified by Zhejiang Province's Identification Agency in 2024." According to the "Administrative Measures for the Identification of High-tech Enterprises" (Guo Ke Fa Huo [2016] No. 32) and the "Guidelines for the Identification and Management of High-tech Enterprises" (Guo Ke Fa Huo [2016] No. 195) and other relevant regulations, a total of 13,336 high-tech enterprises identified by Zhejiang Province’s identification agency in 2024 have officially entered the record-filing public announcement stage.
Youjia (Hangzhou) Biomedical Technology Co., Ltd. ("YOUJIA BIO") has successfully been recognized as a high-tech enterprise due to its innovation capabilities and research strength in the field of nucleic acid drugs. This honor not only reflects the company's comprehensive strength in technology R&D, achievement transformation, and enterprise management but also highlights YOUJIA BIO’s industry status in the high-tech sector.
The recognition of high-tech enterprises is one of the important measures in China to promote industrial innovation and cultivate new economic drivers. Enterprises recognized as high-tech enterprises will enjoy relevant tax preferential policies and special support from governments at all levels, and it also serves as an important proof of the enterprise's technical strength, innovation capability, and industry influence.
Youjia (Hangzhou) Biomedical Technology Co., Ltd. (referred to as "YOUJIA BIO")YOUJIA BIO, established in 2019 by returned overseas postdoctoral researchers and senior industry experts, is a leader in the development of innovative nucleic acid technologies in China. The company is located in the Xiaoshan Economic and Technological Development Zone, Hangzhou, with 40 employees and nearly 1,500 square meters of R&D laboratories. Committed to the vision of making diseases treatable, it aims to meet clinical needs by striving to provide innovative therapeutic solutions.
YOUJIA BIO has established the SEQUAD nucleic acid drug full-process development platform, which can rapidly advance the development of nucleic acid drugs and the industrialization of nucleic acid technology products.YOUJIA BIO is a 5213 Talent Project in Xiaoshan District, and has been approved as a Hangzhou-level R&D center, as well as a Zhejiang Province "Specialized, Fine, Unique, and Innovative" Small and Medium-sized Enterprise.